Brief: Grifols Gets FDA Approval For New Fibrinogen Concentrate, Fesiltytm
19/12/2025 11:12
Dec 19 (Reuters) - Grifols SA GRLS.MC: RECEIVES US FDA APPROVAL FOR NEW FIBRINOGEN CONCENTRATE, FESILTYTM (FIBRINOGEN, HUMAN-CHMT) FESILTY EXPECTED TO BE AVAILABLE IN THE U.S. WITHIN THE FIRST HALF OF 2026 CONCENTRATE, FESILTY APPROVED IN THE U.S. FOR ACUTE BLEEDING EPISODES IN PEDIATRIC AND ADULT PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY Source text Further company coverage: GRLS.MC (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Grifols SA
See all newsSpanish stocks - Factors to watch on June 24
Brief: Grifols Approves Reduction Of Up To 10% Of Its Share Capital
Brief: Grifols Launches Fibrinogen Concentrate For Acute Bleeding Episodes In The U.S.
Brief: Grifols' Egypt Unit Adds €180 Mln Of Additional Investment In Project
Spanish stocks - Factors to watch on June 12